NeuroOne Medical Technologies Files Q1 2025 10-Q

Ticker: NMTC · Form: 10-Q · Filed: May 13, 2025 · CIK: 1500198

Neuroone Medical Technologies CORP 10-Q Filing Summary
FieldDetail
CompanyNeuroone Medical Technologies CORP (NMTC)
Form Type10-Q
Filed DateMay 13, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, financials, quarterly-report

TL;DR

NEUROONE MEDICAL TECHNOLOGIES filed its 10-Q for Q1 2025, check financials.

AI Summary

NeuroOne Medical Technologies Corp. filed its 10-Q for the quarterly period ended March 31, 2025. The company, incorporated in Delaware with its principal executive offices in Eden Prairie, MN, operates in the Surgical & Medical Instruments & Apparatus industry. The filing covers the period ending March 31, 2025, and was submitted on May 13, 2025.

Why It Matters

This filing provides investors with an update on NeuroOne Medical Technologies' financial performance and operational status for the first quarter of 2025.

Risk Assessment

Risk Level: low — This is a standard quarterly financial filing (10-Q) and does not inherently present new risks.

Key Players & Entities

FAQ

What is the exact filing date of this 10-Q report?

The 10-Q report was filed on May 13, 2025.

For what period is this quarterly report?

This quarterly report is for the period ended March 31, 2025.

What is the company's principal executive office location?

The company's principal executive offices are located at 7599 Anagram Drive, Eden Prairie, MN 55344.

What is NeuroOne Medical Technologies Corporation's SIC code?

NeuroOne Medical Technologies Corporation's Standard Industrial Classification code is 3841, for Surgical & Medical Instruments & Apparatus.

What is the SEC file number for NeuroOne Medical Technologies?

The SEC file number for NeuroOne Medical Technologies is 001-40439.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing